Marshall Fordyce, PRESIDENT AND CEO at Vera Therapeutics, Inc. (VERA), sold 32,090 shares at $42.00 ($1.3M) on 2024-10-23, disclosed to the SEC on 2024-10-25.
Scheduled sale ($1.3M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.81 | 12,715 | $506K | 39.3% |
| 2 | $39.81 | 12,715 | $506K | 39.3% |
| 3 | $40.70 | 2,310 | $94K | 7.3% |
| 4 | $41.61 | 600 | $25K | 1.9% |
| 5 | $42.00 | 3,750 | $158K | 12.2% |
| Total | $40.16 avg | 32,090 |
| $1.3M |
| 100% |
| Filing → |
| VERA | SELL | 2026-07-09 | $2.0M | — | Filing → |
| VERA | SELL | 2026-06-24 | $702K | — | Filing → |
| VERA | SELL | 2026-05-13 | $680K | — | Filing → |